Stefania Lalli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Stefania Lalli has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Albanese
Department of Neuroscience, Catholic University of the Sacred Heart, Milano, Italy
14 shared publications - Antonio Emanuele Elia
Department of Clinical Neurosciences, Parkinson and Movement Disorders Unit Fondazione IRCCS Istituto Neurologico Carlo Besta Milan Italy
2 shared publications - Mario Di Giovanni
Unità Operativa di Neurologia, IRCCS Istituto Clinico Humanitas, Rozzano, Milano, Italy
2 shared publications - Paolo Cavallari
Laboratorio Sperimentale di Fisiopatologia Neuromotoria, IRCCS Istituto Auxologico Italiano, 20821 Meda, Italy
2 shared publications Z. Hussain
2 shared publicationsA. Albanese
1 shared publication
Latest Publications
- 23 July 2018
- Published by Wiley in European Journal of Neurology
- Vol. 26 (1) , 5-17
Dystonia: diagnosis and management
Clinical practice in dystonia has greatly evolved in recent years; a synthetic review on patient management is provided here. Dystonia is a movement disorder characterized by sustained or intermittent muscle contractions causing abnormal, often repetitive, movements, postures or both. A recent classification has innovated clinical practice and serves as guidance for clinical assessment: Axis I describes clinical features, whereas Axis II indicates etiology. Dystonia presents with different syndromic aggregations with varied somatic involvement and some common features. There are five recognizable physical signs of dystonia: two main signs (dystonic postures and movements) and three additional signs (gestes antagonistes or tricks, mirror dystonia and overflow dystonia). There is still no validation of diagnostic criteria for the different dystonia syndromes, and many cases with mild phenomenology remain undiagnosed. Patients with dystonia also present non‐motor features that are variably combined with the movement disorder. The features of the most common inherited and acquired dystonia syndromes are reviewed here. There is clear evidence of genetic–environmental interaction in the determinism of dystonia. The diagnostic process is guided by clinical examination and based on specific laboratory examinations. Symptomatic treatments are available for dystonia: botulinum neurotoxin injections are the primary choice for most focal dystonia syndromes; deep brain stimulation is useful in some generalized and non‐generalized syndromes. Additional treatment strategies are currently being assessed.
- 23 July 2018
- Published by Wiley in European Journal of Neurology
- Vol. 26 (1) , 5-17
Dystonia: diagnosis and management
Clinical practice in dystonia has greatly evolved in recent years; a synthetic review on patient management is provided here. Dystonia is a movement disorder characterized by sustained or intermittent muscle contractions causing abnormal, often repetitive, movements, postures or both. A recent classification has innovated clinical practice and serves as guidance for clinical assessment: Axis I describes clinical features, whereas Axis II indicates etiology. Dystonia presents with different syndromic aggregations with varied somatic involvement and some common features. There are five recognizable physical signs of dystonia: two main signs (dystonic postures and movements) and three additional signs (gestes antagonistes or tricks, mirror dystonia and overflow dystonia). There is still no validation of diagnostic criteria for the different dystonia syndromes, and many cases with mild phenomenology remain undiagnosed. Patients with dystonia also present non‐motor features that are variably combined with the movement disorder. The features of the most common inherited and acquired dystonia syndromes are reviewed here. There is clear evidence of genetic–environmental interaction in the determinism of dystonia. The diagnostic process is guided by clinical examination and based on specific laboratory examinations. Symptomatic treatments are available for dystonia: botulinum neurotoxin injections are the primary choice for most focal dystonia syndromes; deep brain stimulation is useful in some generalized and non‐generalized syndromes. Additional treatment strategies are currently being assessed.
- 1 December 2017
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 45, 99-100
Failure of pallidal deep brain stimulation in DYT12-ATP1A3 dystonia
- 1 December 2017
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 45, 99-100
Failure of pallidal deep brain stimulation in DYT12-ATP1A3 dystonia
- 1 March 2015
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 16 (3) , 488-493
Reliability and Validity of the Range of Motion Scale (ROMS) in Patients with Abnormal Postures
ObjectiveSustained abnormal postures (i.e., fixed dystonia) are the most frequently reported motor abnormalities in complex regional pain syndrome (CRPS), but these symptoms may also develop after peripheral trauma without CRPS. Currently, there is no valid and reliable measurement instrument available to measure the severity and distribution of these postures. The range of motion scale (ROMS) was therefore developed to assess the severity based on the possible active range of motion of all joints (arms, legs, trunk, and neck), and the present study evaluates its reliability and validity. MethodsInter- and intra-rater reliability of the ROMS was determined in 16 patients with abnormal sustained postures, who were videotaped following a standard video protocol in a university hospital. The recordings were rated by a panel of international experts. In addition, 30 patients were clinically tested with both the Burke-Fahn-Marsden (BFM) scale as well as the ROMS to assess construct validity. ResultsInter-rater reliability for total ROMS scores showed an intra-class correlation coefficient (ICC) of 0.85. The majority of the scores for the separate joints (13 out of 18) demonstrated an almost perfect agreement with ICCs ranging from 0.81 to 0.94; of the other items, one showed fair, one moderate, and three substantial agreement. The ICCs for the intra-rater reliability ranged from moderate to almost perfect (0.68-0.98). Spearman's correlation coefficients between corresponding body areas as measured with the ROMS or BFM were all above 0.82. ConclusionThe ROMS is a reliable and valid instrument to evaluate the severity and distribution of sustained abnormal postures.
- 1 March 2015
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 16 (3) , 488-493
Reliability and Validity of the Range of Motion Scale (ROMS) in Patients with Abnormal Postures
ObjectiveSustained abnormal postures (i.e., fixed dystonia) are the most frequently reported motor abnormalities in complex regional pain syndrome (CRPS), but these symptoms may also develop after peripheral trauma without CRPS. Currently, there is no valid and reliable measurement instrument available to measure the severity and distribution of these postures. The range of motion scale (ROMS) was therefore developed to assess the severity based on the possible active range of motion of all joints (arms, legs, trunk, and neck), and the present study evaluates its reliability and validity. MethodsInter- and intra-rater reliability of the ROMS was determined in 16 patients with abnormal sustained postures, who were videotaped following a standard video protocol in a university hospital. The recordings were rated by a panel of international experts. In addition, 30 patients were clinically tested with both the Burke-Fahn-Marsden (BFM) scale as well as the ROMS to assess construct validity. ResultsInter-rater reliability for total ROMS scores showed an intra-class correlation coefficient (ICC) of 0.85. The majority of the scores for the separate joints (13 out of 18) demonstrated an almost perfect agreement with ICCs ranging from 0.81 to 0.94; of the other items, one showed fair, one moderate, and three substantial agreement. The ICCs for the intra-rater reliability ranged from moderate to almost perfect (0.68-0.98). Spearman's correlation coefficients between corresponding body areas as measured with the ROMS or BFM were all above 0.82. ConclusionThe ROMS is a reliable and valid instrument to evaluate the severity and distribution of sustained abnormal postures.
- Open Access
- 9 February 2015
- Published by Wiley in European Journal of Neurology
- Vol. 23 (1) , 45-52
Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis
Background and purpose: Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produced in the liver and used for treatment of chronic cholestatic liver diseases. Experimental studies suggest that TUDCA may have cytoprotective and anti‐apoptotic action, with potential neuroprotective activity. A proof of principle approach was adopted to provide preliminary data regarding the efficacy and tolerability of TUDCA in a series of patients with amyotrophic lateral sclerosis (ALS).Methods: As a proof of principle, using a double‐blind placebo controlled design, 34 ALS patients under treatment with riluzole who were randomized to placebo or TUDCA (1 g twice daily for 54 weeks) were evaluated after a lead‐in period of 3 months. The patients were examined every 6 weeks. The primary outcome was the proportion of responders [those subjects with improvement of at least 15% in the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS‐R) slope during the treatment period compared to the lead‐in phase]. Secondary outcomes included between‐treatment comparison of ALSFRS‐R at study end, comparison of the linear regression slopes for ALSFFRS‐R mean scores and the occurrence of adverse events.Results: Tauroursodeoxycholic acid was well tolerated; there were no between‐group differences for adverse events. The proportion of responders was higher under TUDCA (87%) than under placebo (P = 0.021; 43%). At study end baseline‐adjusted ALSFRS‐R was significantly higher (P = 0.007) in TUDCA than in placebo groups. Comparison of the slopes of regression analysis showed slower progression in the TUDCA than in the placebo group (P < 0.01).Conclusions: This pilot study provides preliminary clinical data indicating that TUDCA is safe and may be effective in ALS.
- 9 February 2015
- Published by Wiley in European Journal of Neurology
- Vol. 23 (1) , 45-52
Open AccessTauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis
Background and purpose: Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produced in the liver and used for treatment of chronic cholestatic liver diseases. Experimental studies suggest that TUDCA may have cytoprotective and anti‐apoptotic action, with potential neuroprotective activity. A proof of principle approach was adopted to provide preliminary data regarding the efficacy and tolerability of TUDCA in a series of patients with amyotrophic lateral sclerosis (ALS).Methods: As a proof of principle, using a double‐blind placebo controlled design, 34 ALS patients under treatment with riluzole who were randomized to placebo or TUDCA (1 g twice daily for 54 weeks) were evaluated after a lead‐in period of 3 months. The patients were examined every 6 weeks. The primary outcome was the proportion of responders [those subjects with improvement of at least 15% in the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS‐R) slope during the treatment period compared to the lead‐in phase]. Secondary outcomes included between‐treatment comparison of ALSFRS‐R at study end, comparison of the linear regression slopes for ALSFFRS‐R mean scores and the occurrence of adverse events.Results: Tauroursodeoxycholic acid was well tolerated; there were no between‐group differences for adverse events. The proportion of responders was higher under TUDCA (87%) than under placebo (P = 0.021; 43%). At study end baseline‐adjusted ALSFRS‐R was significantly higher (P = 0.007) in TUDCA than in placebo groups. Comparison of the slopes of regression analysis showed slower progression in the TUDCA than in the placebo group (P < 0.01).Conclusions: This pilot study provides preliminary clinical data indicating that TUDCA is safe and may be effective in ALS.
- 1 August 2012
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 25 (4) , 483-490
Update on dystonia
This review considers the recent literature pertaining to the clinical features, genetics, neuropathology and treatment of dystonia syndromes. The term dystonia indicates at the same time a clinical phenotype and a collection of neurological syndromes mainly of genetic origin. The physical signs contributing to the phenomenology of dystonia have been recently assembled into a coherent set. The molecular genetics of primary dystonia syndromes (DYT1 and DYT6) have been the object of extensive analysis, providing converging views on their causative mechanisms. The relationship between genotype, phenotype, and endophenotypes has been explored for hereditary and sporadic dystonia syndromes. Neurophysiological studies on DYT1 and DYT6 patients, as well as on nonmanifesting carriers, have demonstrated the presence of altered synaptic plasticity. Several recent data indicate a role of dopamine and acetylcholine (ACh) transmission in the pathophysiology of primary dystonia. Recent findings have led to novel, testable hypotheses on cellular mechanisms and physiopathological abnormalities underlying dystonia. Neurophysiological studies, imaging data and animal models support the view that corticostriatal, cerebellar, and dopaminergic dysfunctions converge to produce the pathophysiological abnormalities of dystonia.
- 1 August 2012
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 25 (4) , 483-490
Update on dystonia
This review considers the recent literature pertaining to the clinical features, genetics, neuropathology and treatment of dystonia syndromes. The term dystonia indicates at the same time a clinical phenotype and a collection of neurological syndromes mainly of genetic origin. The physical signs contributing to the phenomenology of dystonia have been recently assembled into a coherent set. The molecular genetics of primary dystonia syndromes (DYT1 and DYT6) have been the object of extensive analysis, providing converging views on their causative mechanisms. The relationship between genotype, phenotype, and endophenotypes has been explored for hereditary and sporadic dystonia syndromes. Neurophysiological studies on DYT1 and DYT6 patients, as well as on nonmanifesting carriers, have demonstrated the presence of altered synaptic plasticity. Several recent data indicate a role of dopamine and acetylcholine (ACh) transmission in the pathophysiology of primary dystonia. Recent findings have led to novel, testable hypotheses on cellular mechanisms and physiopathological abnormalities underlying dystonia. Neurophysiological studies, imaging data and animal models support the view that corticostriatal, cerebellar, and dopaminergic dysfunctions converge to produce the pathophysiological abnormalities of dystonia.
- 16 February 2012
- Published by Wiley in Movement Disorders
- Vol. 27 (4) , 533-538
Epidural premotor cortical stimulation in primary focal dystonia: Clinical and 18F‐fluoro deoxyglucose positron emission tomography open study
The aim of this study was to evaluate the efficacy and safety of epidural premotor stimulation in patients with primary focal dystonia. Seven patients were selected: 6 had cervical dystonia and 1 had right upper limb dystonia. In 2 patients, sustained muscle contractions led to a prevalently fixed head posture. Patients with cervical dystonia received a bilateral implant, whereas the patient with hand dystonia received a unilateral implant. Neurological and neuropsychological evaluations were performed before surgery (baseline), and 1, 3, 6, and 12 months afterward. The Burke‐Fahn‐Marsden scale (BFMS) and the Toronto Western spasmodic torticollis rating scale (TWSTRS) were administered at the same time points. Patients underwent resting 18F‐fluorodeoxyglucose (FDG) positron emission tomography (PET) scans, before and 12 months after surgery. No adverse events occurred. An overall improvement was observed on the BFMS and TWSTRS after surgery. Patients with prevalently fixed cervical dystonia had a reduced benefit. Presurgical neuroimaging revealed a significant bilateral metabolic increase in the sensorimotor areas, which was reduced after surgery. © 2012 Movement Disorder Society
- 16 February 2012
- Published by Wiley in Movement Disorders
- Vol. 27 (4) , 533-538
Epidural premotor cortical stimulation in primary focal dystonia: Clinical and 18F‐fluoro deoxyglucose positron emission tomography open study
The aim of this study was to evaluate the efficacy and safety of epidural premotor stimulation in patients with primary focal dystonia. Seven patients were selected: 6 had cervical dystonia and 1 had right upper limb dystonia. In 2 patients, sustained muscle contractions led to a prevalently fixed head posture. Patients with cervical dystonia received a bilateral implant, whereas the patient with hand dystonia received a unilateral implant. Neurological and neuropsychological evaluations were performed before surgery (baseline), and 1, 3, 6, and 12 months afterward. The Burke‐Fahn‐Marsden scale (BFMS) and the Toronto Western spasmodic torticollis rating scale (TWSTRS) were administered at the same time points. Patients underwent resting 18F‐fluorodeoxyglucose (FDG) positron emission tomography (PET) scans, before and 12 months after surgery. No adverse events occurred. An overall improvement was observed on the BFMS and TWSTRS after surgery. Patients with prevalently fixed cervical dystonia had a reduced benefit. Presurgical neuroimaging revealed a significant bilateral metabolic increase in the sensorimotor areas, which was reduced after surgery. © 2012 Movement Disorder Society
- 6 September 2011
- Published by Informa Healthcare in Expert Opinion on Medical Diagnostics
- Vol. 5 (6) , 483-500
Diagnostic issues in childhood and adult dystonia
Introduction: There is a general agreement among movement disorder specialists that the recognition of dystonia may be underestimated. In parallel, the growing interest and the improving knowledge of genetic and physiopathological aspects of dystonias require systematization. Areas covered: This review focuses on the phenomenology and etiology of pediatric and adult dystonias. It is designed to provide practical help for neurologists and neuropediatricians to make appropriate diagnoses and plan the therapeutical management of these disorders. The reader will get a systematization of the main etiological and diagnostic aspects that differentiate child-onset from adult-onset dystonias. The reader will also gain insights into specific treatments or cures. Expert opinion: Because dystonia can vary in clinical presentation and etiology, proper diagnosis and classification of these disorders are important in making therapeutic decisions.
- 6 September 2011
- Published by Informa Healthcare in Expert Opinion on Medical Diagnostics
- Vol. 5 (6) , 483-500
Diagnostic issues in childhood and adult dystonia
Introduction: There is a general agreement among movement disorder specialists that the recognition of dystonia may be underestimated. In parallel, the growing interest and the improving knowledge of genetic and physiopathological aspects of dystonias require systematization. Areas covered: This review focuses on the phenomenology and etiology of pediatric and adult dystonias. It is designed to provide practical help for neurologists and neuropediatricians to make appropriate diagnoses and plan the therapeutical management of these disorders. The reader will get a systematization of the main etiological and diagnostic aspects that differentiate child-onset from adult-onset dystonias. The reader will also gain insights into specific treatments or cures. Expert opinion: Because dystonia can vary in clinical presentation and etiology, proper diagnosis and classification of these disorders are important in making therapeutic decisions.
- 1 June 2011
- Published by Elsevier in Clinical Neurophysiology
- Vol. 122, S91
P7.8 Premotor cortical stimulation in primary dystonia
- 1 June 2011
- Published by Elsevier in Clinical Neurophysiology
- Vol. 122, S91
P7.8 Premotor cortical stimulation in primary dystonia
- 5 October 2010
- Published by Wiley in Movement Disorders
- Vol. 25 (16) , 2899
Distinguishing scan without evidence of dopaminergic depletion patients with asymmetric resting tremor from Parkinson's disease: A clinical diagnosis of dystonia is required
- 5 October 2010
- Published by Wiley in Movement Disorders
- Vol. 25 (16) , 2899
Distinguishing scan without evidence of dopaminergic depletion patients with asymmetric resting tremor from Parkinson's disease: A clinical diagnosis of dystonia is required